SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending amid discussions around its earnings report, with community members debating whether the results justify the current stock price. Initial reactions were mixed due to some outlets initially reporting incorrect numbers. Bullish investors cite customer asset growth and potential for future gains, while others express concerns about dilution and overall market conditions.

SSgA Active Trust - SPDR S&P 500 ETF Trust

Amidst broad market volatility and tech sector struggles, the SPY is trending as the community debates whether this pullback signals a buying opportunity or the start of a deeper correction. Discussion revolves around potential catalysts, including the impact of economic data, Fed policy, and geopolitical events, while some traders point to technical indicators suggesting oversold conditions.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing significant intraday volatility, with community members pointing to a broader market correction despite strong earnings from names like NVDA. Discussions revolve around potential factors such as liquidity concerns and the unwinding of overleveraged positions, while some traders speculate about a possible bear market or a coming rally into the holiday season. Community members are actively debating whether to buy the dip or brace for further declines.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending after a significant investment in Performance Drone Works (PDW), a U.S. defense technology company specializing in AI-enabled combat robotics, as well as an $8.2M contract win. The community is discussing the potential impact of this investment on production scaling and Ondas's position in the autonomous defense sector. Despite market volatility, many express optimism about ONDS's growth potential and ability to secure further contracts.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors digest recent earnings, a planned move to the Nasdaq, and a CEO transition. Community members are discussing whether Walmart is a safe haven amid market uncertainty, while also weighing the impact of consumer spending trends and SNAP benefits. Some traders are analyzing technical patterns, while others are highlighting Walmart's push into e-commerce and AI.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending due to concerns about the small-cap sector's vulnerability amid fading rate cut hopes and institutional put buying, with community members closely watching key support levels and potential downside risks. Discussions revolve around whether the ETF can reclaim crucial price levels, as some traders point to technical formations suggesting further declines while others anticipate a potential oversold bounce. Overall, the conversation highlights uncertainty and a cautious outlook for small-cap performance in the near term.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors discuss its recent price decline and potential for a rebound ahead of upcoming earnings, with some citing market manipulation and overselling as key factors; the community is also weighing the impact of potential profitability and new partnerships on the stock's future performance amid broader concerns about the EV sector and the overall market.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology (MU) is trending amidst a broader market downturn, with community chatter focused on a recent price drop from multi-year highs. Despite positive analyst ratings and long-term growth prospects tied to AI-driven memory demand, some traders believe MU was overbought, leading to profit-taking and increased volatility. Traders are closely watching for a potential bounce and upcoming earnings data.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is gaining traction within its community, with many highlighting its dedicated following and meme-driven engagement. Discussions center around the project's potential as it aims for a $1 million market cap, with community members expressing excitement about its growth and "infectious" nature within the Solana ecosystem.

Pump.fun

Pump.fun ($PUMP) is trending as the community rallies around the project and its ecosystem coins on the Solana blockchain, particularly $PMV and $WAGMI.  Community members highlight the dedication and hard work within the community, with some focusing on a trading AI called $GHOSTFI and a token buyback program. Bullish sentiment is strong, with many anticipating further growth and new projects launching on the platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...

Precision Oncology Approaches Drive $312B Market Transformation

Precision Oncology Approaches Drive $312B Market Transformation Precision Oncology Approaches Drive $312B Market Transformation PR Newswire VANCOUVER, Oct. 17, 2025 USA News Group News Commentary...

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape Next-Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire VANCOUVER, BC, Oct. 15, 2025 USA News Group...

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...

Shares of GT Biopharma had their best trading day in more than nine months after the company shared encouraging progress from its ongoing Phase 1 trial of GTB-3650, an experimental treatment for patients with relapsed or refractory CD33-positive blood cancers.The stock jumped 43.7% to $1.08 at Wednesday’s close, before slipping 10.5% in after-hours trading.The clinical-stage biotech company said enrollment in the study’s dose-escalation groups is progressing smoothly and remains “well on track.” Both patients in Cohort 3 have now begun treatment, with no signs of dose-limiting toxicities or tolerability issues so far.&nbsp;The company added that the first patient in Cohort 3 has shown “promising evidence of immune activation,” matching the levels of activity seen in patients from the two earlier, lower-dose groups.GT Biopharma's trial will evaluate the safety, pharmacokinetics/pharmacodynamics of GTB-3650, and evidence of immune activation. GTB-3650 will use the company's TriKE platform to recruit natural killer (NK) cells to fight cancer.The Phase 1 study can enroll up to 14 patients, with two people in each of seven planned dosing groups. The lowest dose starts at 1.25 micrograms per kilogram per day and could go up to 100 micrograms per kilogram per day in the highest group. Each patient will take the drug in two-week treatment cycles, with two weeks on therapy followed by two weeks off, for as long as four months if they continue to show signs of clinical benefit.If Cohort 3 is dosed without any problems, GT Biopharma anticipates dosing the first patient in Cohort 4 by the end of 2025. The dose level can be increased further if warranted. The company expects to provide an update on additional data by the end of 2025 and in the first quarter of 2026 as it moves to the higher dose levels in the trial that may yield more robust therapeutic effects.On Stocktwits, retail sentiment for GT Biopharma was ‘extremely bullish’ amid a 2,933% surge in 24-hour message volume.One user said that GT Biopharma shares appeared to be gaining strong upward momentum and could move toward double-digit levels.&nbsp;<stembedurl>https://stocktwits.com/Illbeyourhuckleberree/message/631516421</stembedurl>Another user commented that the company’s cancer therapy showed significant promise, with the potential for substantial long-term returns.<stembedurl>https://stocktwits.com/Djdanny/message/631566315</stembedurl><a href="https://stocktwits.com/symbol/GTBP">GT Biopharma’s stock</a> has declined 65% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

GT Biopharma’s stock (GTBP) has declined 65% so far in 2025. (Photo credit: Getty Images)

GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally

The biotech firm reported smooth progress in its Phase 1 trial of GTB-3650, with no safety issues and early signs of immune activation in the latest dosing group. 

Equity

Shares of GT Biopharma, Inc. surged more than 21% on Tuesday before slipping after-hours as investors reacted to the company's unexpected shift in its financing strategy.&nbsp;The announcement sent 24-hour message volume on Stocktwits skyrocketing by 18,700%, marking the highest spike among biotech stocks, with trading volume more than doubling from its daily average.The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.&nbsp;The filing had not yet been declared effective, and no securities had been sold under the proposed offering.&nbsp;Instead, GT Biopharma opted for a direct warrant exercise agreement, securing immediate funds while offering new unregistered warrants to investors.Under the new arrangement, the company entered into definitive agreements to exercise existing warrants to purchase 302,069 shares of common stock, with an exercise price of $4.35 per share.&nbsp;The move is expected to generate approximately $700,000 in gross proceeds before deducting placement agent fees and offering expenses.The offering is anticipated to close by Thursday, with proceeds earmarked for working capital and general corporate purposes.On Stocktwits, retail investors' reactions were mostly positive to the company's financing shift.&nbsp;One user described the move as "going in the right direction."&nbsp;<stembedurl>https://stocktwits.com/Rassy40/message/605686808</stembedurl>Another pointed out that short sellers had expected dilution due to the S-1 registration, but they may now be forced to cover with the offering canceled.&nbsp;<stembedurl>https://stocktwits.com/Annet_why_net/message/605691704</stembedurl>However, some traders indicated they were still waiting for a more attractive entry point.Short interest on GTBP shares has jumped from 0.6% at the start of the year to 8.8% at the end of last week, per Koyfin data.Beyond the financing development, Roth MKM remains optimistic about GT Biopharma's clinical pipeline.&nbsp;The research firm expects the company to release initial data later this year from its Phase 1 trial evaluating GTB-3650, its therapy targeting CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome.GT Biopharma ended 2024 with approximately $4 million in cash, which Roth MKM estimates is sufficient to fund operations into the second quarter of this year.&nbsp;The research firm maintained a 'Buy' rating on the stock, with an $11 price target, implying a potential fivefold increase from current levels.The company's stock has lost more than 17% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak

The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.

Recap: GT Biopharma Q4 Earnings

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...

GT Biopharma trading halted, news pending

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GT Biopharma announces 1-for-30 reverse stock split

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

GTBP
GT Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GTBP News

GTBPGT Biopharma Inc